Calciscon AG

medical devices

About

Calciscon develops and markets diagnostic devices for the assessment of calcification-related cardiovascular (CV) disease. CV disease is the leading cause of death worldwide, and vascular calcification is a most important driver of CV disease. Calciscon has developed and markets the T50 test, a novel and unique measurement of calcification. This medical information is critical to enable individualized care, and pivotal to reduce calcification and prevent cardiovascular disease. The T50 addresses a multi-billion market opportunity, and Calciscon will initially target patients with advanced chronic kidney disease (CKD), the patient group with the highest rate of calcification-related CV events (20x higher then normal population). The T50 test first enables the doctor to identify highest-risk patients, and then drives the selection of the most effective therapy to critically reduce calcification, to improve patient CV prognosis.

Technologies

Outlook Microsoft Office 365 Google Tag Manager Apache JQuery 1.11.1

Keywords

medical equipment manufacturing t50 calciprotein crystallization test cpp measurement amniotic fluid testing healthcare laboratory services t50 test oxidative stress markers calcification propensity calciprotein particles ckd progression marker cardiovascular event predictor biotechnology biomarker analysis disease progression monitoring animal model t50 measurement inflammation biomarkers clinical measurement services cardiovascular risk prediction b2b sample shipment and handling calcification driver fetal cord blood analysis calcification risk assessment offices of all other health practitioners clinical laboratory testing cpp measurement methods services calcification therapy guidance chronic kidney disease diagnostics

Location

46 Aarbergstrasse, Biel/Bienne, Canton of Bern, Switzerland, 2503

Related Companies

Companies in the same industry